Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer

Basit Öğe Kaydı
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorÜrün, Müslih
dc.contributor.authorGüner, Gürkan
dc.contributor.authorSezgin, Yasin
dc.contributor.authorSakin, Abdullah
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2025-06-03T12:56:43Z
dc.date.available2025-06-03T12:56:43Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractBackground: This retrospective study from a single center included 289 patients diagnosed with advanced non-small cell lung cancer (NSCLC) between 2010 to 2017 and aimed to evaluate the effects of body mass index (BMI) on overall survival. Material/Methods: This retrospective study involved 289 patients diagnosed with metastatic-stage NSCLC at a single institution between January 2010 and December 2017. Patients were categorized into 2 groups based on their BMI at diagnosis: those with a BMI <25 kg/m2 and those with a BMI 325 kg/m2. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with overall survival. Results: A total of 289 patients (241 men, 48 women) were included in the study, with a mean age of 60.1±11.1 years. Among them, 175 patients (60.6%) had a BMI less than 25 kg/m2. Multivariate analysis revealed that BMI, pathological diagnosis, and complete response after first-line treatment were independently associated with survival in patients with lung cancer. Predicted survival time was significantly shorter in the BMI <25 group than in the BMI 325 group (9.3 months vs 13.0 months, P<0.05). Conclusions: The study demonstrated that a higher BMI at the time of diagnosis is associated with improved overall survival in patients with de novo metastatic NSCLC. BMI may serve as an important prognostic factor in this patient population. Future prospective, multi-center studies are necessary to further validate the role of BMI in predicting survival outcomes in NSCLC patients across different treatment modalities. © Med Sci Monit.
dc.identifier.citationÜrün, M., Güner, G., Sezgin, Y., Sakin, A., & Kılıçkap, S. (2024). Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 30, e946751.
dc.identifier.doi10.12659/MSM.946751
dc.identifier.issn12341010
dc.identifier.pmid39690723
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.12659/MSM.946751
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7277
dc.identifier.volume30
dc.identifier.wosWOS:001380858100001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorKılıçkap, Saadettin
dc.institutionauthoridSaadettin Kılıçkap / 0000-0003-1637-7390
dc.language.isoen
dc.publisherInternational Scientific Information, Inc.
dc.relation.ispartofMedical Science Monitor
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBody Mass Index
dc.subjectCarcinoma
dc.subjectNon-Small-Cell Lung
dc.subjectSurvival
dc.subjectObesity
dc.titleAssociation Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
946751.pdf
Boyut:
421.88 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu